Literature DB >> 24370198

Outcome of surgically resected thymic carcinoma: a multicenter experience.

Pier Luigi Filosso1, Francesco Guerrera2, Angelo Erino Rendina3, Giulia Bora2, Enrico Ruffini2, Domenico Novero4, Luigi Ruco5, Domenico Vitolo6, Marco Anile7, Mohsen Ibrahim3, Caterina Casadio8, Ottavio Rena8, Alberto Terzi9, Paraskevas Lyberis2, Alberto Oliaro2, Federico Venuta7.   

Abstract

OBJECTIVE: Thymic carcinoma (TC) is a rare and invasive mediastinal tumor, with poor prognosis. Most of the previous published papers are single-institution based, reporting small series of patient, sometimes including palliative resection. This study collected patients with TC treated in 5 high-volume Italian Thoracic Surgery Institutions.
METHODS: A multicenter retrospective study of patients operated for TC between 2000 and 2011 was conducted. Exclusion criteria were: Neuroendocrine thymic neoplasms, debulking/palliative resection and tumor biopsy. Cause specific survival (CSS) was the primary endpoint.
RESULTS: Four hundred and seventy-eight patients underwent surgery for thymic malignancies: 40 of them (8.4%) had TC. Eleven (27.5%) received induction chemotherapy because of their radiological invasiveness. A complete resection (R0) was achieved in 36 (90%; 9/11 submitted to induction chemotherapy). Adjuvant radio/chemotherapy was offered to 37 patients, according to the type of surgical resection and tumor invasiveness. Three, 5 and 10-year survival rates were 79%, 75% and 58%. Recurrences developed in 10 patients. R0 resection (p<0.0003) and absence of tumor recurrences (p=0.03) resulted significant prognostic factors at univariate analysis. Independent CSS predictor was the achievement of a complete resection (p<0.05).
CONCLUSIONS: TC is a rare and invasive mediastinal tumor. A multimodal approach is indicated especially in TC invasive forms. The achievement of a complete surgical resection is fundamental to improve survival.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Masaoka staging system; Myasthenia Gravis; Outcome; Surgery; Thymic carcinoma; Thymus

Mesh:

Year:  2013        PMID: 24370198     DOI: 10.1016/j.lungcan.2013.11.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

2.  Isolated splenic metastasis from a thymic carcinoma: A case report.

Authors:  Dongmei Chen; Xiangying Meng; Yaowei Zhao; Shikai Wu
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

Review 3.  Neuroendocrine tumors of the thymus.

Authors:  Pier Luigi Filosso; Enrico Ruffini; Paolo Solidoro; Matteo Roffinella; Paolo Olivo Lausi; Paraskevas Lyberis; Alberto Oliaro; Francesco Guerrera
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group.

Authors:  Annemarie Shepherd; Gregory Riely; Frank Detterbeck; Charles B Simone; Usman Ahmad; James Huang; Robert Korst; Arun Rajan; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2016-11-19       Impact factor: 15.609

5.  Radiographic Predictors of Resectability in Thymic Carcinoma.

Authors:  Sara A Hayes; James Huang; Jennifer Golia Pernicka; Jane Cunningham; Junting Zheng; Chaya S Moskowitz; Michelle S Ginsberg
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

6.  Thymic carcinoma patients with myasthenia gravis exhibit better prognoses.

Authors:  Wenya Li; Zhifeng Miao; Xudong Liu; Qigang Zhang; Lei Sun; Peiwen Li; Wenke Liu; Lin Zhang
Journal:  Int J Clin Oncol       Date:  2015-07-03       Impact factor: 3.402

7.  Coincidence of thymoma and breast cancer and in a 56-year-old female patient.

Authors:  Evangelia Athanasiou; Electra Michalopoulou-Manoloutsiou; Mattheos Bobos; Dimitris I Hatzibougias; Paul Zarogoulidis; Nikolos Katsikogiannis; Eirini Sarika; Ilias Karapantzos; Nikolaos Barbetakis; Dimitrios Paliouras; Fotis Chatzinikolaou; Charalampos Charalampidis; Ioanna Kougioumtzi; Alexandros Kolettas; Andreas Bakas; Keraso Tzelepi; Efstratios Kalaitzis; Kosmas Tsakiridis
Journal:  Ann Transl Med       Date:  2016-11

8.  Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.

Authors:  Pier Luigi Filosso; Xiaopan Yao; Enrico Ruffini; Usman Ahmad; Alberto Antonicelli; James Huang; Francesco Guerrera; Federico Venuta; Dirk van Raemdonck; William Travis; Marco Lucchi; Andreas Rimner; Pascal Thomas; Walter Weder; Gaetano Rocco; Frank Detterbeck; Robert Korst
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-31       Impact factor: 4.191

9.  Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma.

Authors:  Qianwen Liu; Xiayu Fu; Xiaodong Su; Xin Wang; Yijun Zhang; Hong Yang; Yi Hu; Jing Wen; Jianhua Fu
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

10.  Adjuvant chemotherapy improves survival outcomes after complete resection of thymic squamous cell carcinoma: a retrospective study of 116 patients.

Authors:  Lanting Gao; Changlu Wang; Mina Liu; Wentao Fang; Changxing Lv; Xiaolong Fu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.